Trovagene Gets $15M Credit Facility to Fund Cancer Monitoring Tech Development, Commercialization | GenomeWeb

NEW YORK (GenomeWeb) – Trovagene has secured a $15 million unrestricted debt facility from Silicon Valley Bank and Oxford Finance, the company said on Tuesday.

The San Diego-based firm will use the capital to support development and commercialization of its urine-based cell-free oncogene mutation cancer monitoring technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.